Perseus Proteomics Inc. (TYO:4882)
229.00
+21.00 (10.10%)
Mar 5, 2026, 3:30 PM JST
Perseus Proteomics Revenue
Perseus Proteomics had revenue of 43.10M JPY in the quarter ending December 31, 2025, with 82.02% growth. This brings the company's revenue in the last twelve months to 140.41M, up 26.06% year-over-year. In the fiscal year ending March 31, 2025, Perseus Proteomics had annual revenue of 120.00M with 20.00% growth.
Revenue (ttm)
140.41M
Revenue Growth
+26.06%
P/S Ratio
21.85
Revenue / Employee
4.39M
Employees
32
Market Cap
3.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 120.00M | 20.00M | 20.00% |
| Mar 31, 2024 | 100.00M | 6.00M | 6.38% |
| Mar 31, 2023 | 94.00M | 23.00M | 32.39% |
| Mar 31, 2022 | 71.00M | 4.00M | 5.97% |
| Mar 31, 2021 | 67.00M | -18.00M | -21.18% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.47T |
| Astellas Pharma | 2.06T |
| Daiichi Sankyo Company | 2.05T |
| Chugai Pharmaceutical | 1.26T |
| Ono Pharmaceutical | 509.35B |
| Kyowa Kirin | 496.83B |
| Santen Pharmaceutical | 287.99B |
| JCR Pharmaceuticals | 37.55B |